Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chromodomain-helicase-DNA-binding protein 4 (CHD4)
- Target
- CHD4
- Molecular classification
- Chromatin remodeler, Helicase, Transcription factor (component), ATPase (ATP-dependent enzyme), Histone modification (NuRD complex component)
01
Overview
Chromodomain-helicase-DNA-binding protein 4 (CHD4) is an ATP-dependent chromatin-remodeling enzyme of the SNF2/RAD54 helicase family and is a core component of the nucleosome remodeling and deacetylase (NuRD) complex[2][1][5]. It binds and distorts nucleosomal DNA and plays a key role in epigenetic transcriptional repression, DNA damage repair (notably via homologous recombination), and arrest of transcription in response to DNA damage[2][5][1]. CHD4 has been implicated in neurogenesis, and its dysfunction or mutation is associated with several cancers, developmental syndromes (notably Sifrim-Hitz-Weiss syndrome), and is a known autoantigen in dermatomyositis[2][5][4]. Its targeting is of interest for modulating gene expression and DNA repair pathways in disease contexts[1][2].
- Other names
- Chromodomain helicase DNA binding protein 4CHD-4Mi-2bMi2-betaATP-dependent helicase CHD4Mi-2 autoantigen 218 kDa proteinSIHIWESMi2-BETACHD4
02
Mechanism of action
Inhibition or modulation of chromatin remodeling activity (NuRD complex); Modulation of DNA damage repair pathways via NuRD complex inhibition or stabilization
03
Biological functions
Chromatin remodelingTranscriptional repressionDNA damage responseEpigenetic regulationNeurogenesis
04
Disease associations
CancerSifrim-Hitz-Weiss syndromePallister-Hall syndromeAutoimmune myositis (dermatomyositis autoantigen)Other developmental syndromes
05
Safety considerations
Broad epigenetic roles leading to potential effects on cell proliferation and differentiationRisk of off-target chromatin remodeling and gene repression events
06
Biomarkers
Anti-Mi-2 autoantibody (biomarker for dermatomyositis)Somatic mutations in CHD4 (mutational biomarker in endometrial and other cancers)
Beyond the preview
Go deeper on Chromodomain-helicase-DNA-binding protein 4 (CHD4).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chromodomain-helicase-DNA-binding protein 4 (CHD4).